期刊文献+

福善美结合钙尔奇D治疗绝经后骨质疏松的疗效观察

Observation on Clinical Healing Effect of Fosamax Combining Callrate D for Treating Female Postmenopausal Osteoporosis
下载PDF
导出
摘要 目的探讨福善美与钙尔奇D联合治疗绝经后骨质疏松症(PMO)的临床疗效。方法156例绝经后骨质疏松患者随机分为治疗组87例和对照组69例,治疗组接受福善美、钙尔奇D联合治疗;对照组仅口服钙片治疗,均经1年的治疗。观察两组治疗前后VRS疼痛评分、血钙、血磷和碱性磷酸酶变化情况,双能X线吸收仪(DEXA)测量两组治疗前后腰椎(kq)前后位密度(BMD)的变化情况,并进行统计学分析。结果治疗组和对照组治疗前后骨密度BMD分别为0.876+0157、0.947±0.203和0.879±0149、0.881±0.161,治疗组治疗前后骨密度BMD变化有显著差异(P〈0.05)。对照组无显著差异(P〉0.05);两组治疗后的骨密度BMD有显著差异(P〈0.05)。治疗组骨痛VAS评分总改善效率明显高于对照组(P〈0.05)。两组血钙、血磷和对照组碱性磷酸酶治疗前后无明显改变(P〉0.05),但治疗组碱性磷酸酶较治疗前明显下降(P〈0.05)。结论福善美与钙尔奇D联合治疗绝经后骨质疏松能显著改善骨痛并提高骨密度。 Objective To observe the herapeulie effects of alendronate(Fosamax) combining Callrate D for treating femal postmenopausal osteoporosis. Methods 156 cases of postmenopausal steoporosis patients were randomized into the treatment group(87 cases) and the control group(69 cases), the treatment groups taking Fosamax, Callrate D, and at the same time, the control group taking Callrate D only. After one year's treatment, to observe the VRS bone pain score, serum calcium, serum phosphate, alkaline phosphatase (ALP). The BMD at the lumbar spine (L-~4) measured by dula energy X-ary absorptiometry, before and after treatment of the two groups. Result The bone mineral density before and after treatment bewteen the treatment group and'controlr group were 0.876±0.157, 0.947±0.203 and 0.879±0.149, 0.881±0.161, before and after treatmnt of the treatment goup, the bone mineral density were significantly different(P〈0.05) while the control group showed no significant diference(P〉0.05). The treatment group VRS bone pain evaluation obviously superior the control group(P〈0.05). The serum calcium, serum phosphate, alkaline phosphatase(ALP) before and after treatment of the two groups showed no significant diference (P〉0.05). The alkaline phosphatase (ALP) after treatment bewteen the treatment group and controlr group were decreated differentily (P〈0.05). Conclusion Fosamax combining Callrate D for treating femal postmenopausal osteoporosis can signiifcantly reduce the pain and increase the lumbar verlebra BMD.
作者 张咏梅 庄青山 ZHANG Yong-mei, ZHUANG Qing-shan (Department of Spinal Surgery, Weifang People's Hospital of Shandong Province, Weifang 261041, China)
机构地区 潍坊市人民医院
出处 《医学信息》 2011年第23期269-270,共2页 Journal of Medical Information
关键词 绝经后骨质疏松症 福善美 钙尔奇D 骨痛 骨密度 Postmenopausal Osteoporos Fosama Callrate D Bone pain BMD
  • 相关文献

参考文献5

  • 1Melton LJ,Arkinson EJ,O'Falkon,et al.Long -term fracture prediction by bone mineral density assessed at different skeletal sites[J].J Bone Miner Res,1993,8:1227-1233.
  • 2Cummings SR.Bone density at variours site for prediction of hip fracture[J].Lancet,1993,341:962-963.
  • 3Kanis JA,Johnell O,Oden A,et al.Ten year probabilities of osteoporotic frac-tures according to BMD and diagnostic thresholds[J].Osteoporosis International,2001,12(10):989-995.
  • 4Dennis MB,Desmond ET,Douglas C,et al.Fracuure risk reduction with alen-dronate in women with osteoporosis:the fracture intervention trial[J].The Journal of Clinical Endocrinology & Metabolism,2000,85(11):4118-4124.
  • 5Takada J,Iba K,Imoto K,et al.Changes in bone resorption markers among Japanese patients with postmenopausal osteoprosis treated with alendronate and risedronate[J].J Bone Miner Metab,2007,25(2):142-146.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部